Five-year follow-up of early intervention peanut oral immunotherapy

Abstract

There is a clear need for long-term outcome and safety data amongst participants treated with oral immunotherapy (OIT). A recent meta-analysis of 12 peanut OIT trials showed that peanut OIT versus no OIT increased anaphylaxis risk.1 Furthermore, a retrospective review of 270 clinical allergy patients undergoing peanut OIT found 28 epinephrine-treated reactions occurring during maintenance therapy, 10 of which were beyond the first 6 months of maintenance therapy.2 An improved understanding of the net health benefits of OIT is especially critical given the recent Food and Drug Administration approval of Palforzia, which will likely greatly expand the use of peanut OIT.